You may get your wish. Lc said earlier this imugene is only interested in the solid tumour market, no plans to become a car-t company yet here are car-t in blood cancer company. Azer-cell is 3 years from registration and does not fit in with oncarlytics time frame. Why the rush to license this drug at the destruction of the sp. Could a buy out for CF33 be happening and we are watching the birth imugene 2.0 car-t company merged with rad, chm. Just a wild thought
Rubbing my ball, page-1468
-
- There are more pages in this discussion • 225 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
-0.002(3.45%) |
Mkt cap ! $409.9M | |||
| Open | High | Low | Value | Volume |
| 5.7¢ | 5.9¢ | 5.6¢ | $1.124M | 19.72M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 933589 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 776750 | 4 |
View Market Depth
| Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |